A binary Xpovio catalyst is set for March.
ApexOnco Front Page
Recent articles
BeOne terminates a MUC1-targeting project.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
Full data from Edge-Gastric are presented at ESMO.
The first TUB-040 data come just after Tubulis raised €308m.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
